<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01159600</url>
  </required_header>
  <id_info>
    <org_study_id>1245.23</org_study_id>
    <secondary_id>2009-016258-41</secondary_id>
    <nct_id>NCT01159600</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the current study is to investigate the efficacy, safety and tolerability of
      two doses of BI 10773 compared to placebo given for 24 weeks as add-on therapy to metformin
      or metformin plus sulfonylurea in patients with Typ 2 Diabetes Mellitus with insufficient
      glycaemic control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c Change From Baseline</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Change from baseline in HbA1c after 24 weeks.
For open-label groups the descriptive mean is provided, for randomised groups adjusted means are provided. The means are adjusted separately for metformin alone and metformin plus sulphonylurea background medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Weight Change From Baseline</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Body weight change from baseline after 24 weeks.
For open-label groups the descriptive mean is provided, for randomised groups adjusted means are provided. The means are adjusted separately for metformin alone and metformin plus sulphonylurea background medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Daily Plasma Glucose (MDG) Change From Baseline</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Change from baseline in mean daily glucose (MDG) using the 8-point blood glucose profile, after 24 weeks of treatment.
For open-label groups the descriptive mean is provided, for randomised groups adjusted means are provided. The means are adjusted separately for metformin alone and metformin plus sulphonylurea background medication.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Confirmed Hypoglycaemic Adverse Events</measure>
    <time_frame>From first intake of randomised trial medication until 7 days after last trial medication intake, up to 231 days</time_frame>
    <description>Number of patients with confirmed hypoglycaemic events, as reported as adverse events.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1504</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI 10773 Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 once daily high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching BI 10773</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 open-label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 once daily high dose open label</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 once daily low dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo identical to BI 10773 high dose</intervention_name>
    <description>Placebo tablets matching BI 10773 high dose</description>
    <arm_group_label>BI 10773 Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo identical to BI 10773 low dose</intervention_name>
    <description>Placebo tablets matching BI 10773 low dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 tablets once daily high dose open label</description>
    <arm_group_label>BI 10773 open-label</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 tablets once daily high dose</description>
    <arm_group_label>BI 10773 Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo identical to BI 10773 low dose</intervention_name>
    <description>Placebo tablets matching BI 10773 low dose</description>
    <arm_group_label>BI 10773 Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 tablets once daily low dose</description>
    <arm_group_label>BI 10773 Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo identical to BI 10773 high dose</intervention_name>
    <description>Placebo tablets matching BI 10773 high dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Diagnosis of type 2 diabetes mellitus prior to informed consent

          2. Male and female patients on a diet and exercise regimen who are pre-treated with
             immediate release metformin or immediate release metformin plus sulfonylurea (see
             below for minimum doses). The treatment regimen has to be unchanged for 12 weeks prior
             to randomisation.

             Minimum dose for metformin: &gt; or = 1500 mg/day or maximum tolerated dose or maximum
             dose according to local label Minimum dose for sulfonylurea: &gt; or = half of the
             maximal recommended dose or maximum tolerated dose or maximum dose according to local
             label

          3. HbA1c of &gt; or = 7.0% and &lt; or = 11% at Visit 1 (screening) in order to be eligible for
             randomised treatment HbA1c of &gt; 11% at Visit 1 (screening) in order to be eligible for
             the open-label treatment arm (25 mg BI 10773)

          4. Age&gt; or = 18

          5. Body Mass Index (BM)I &lt; or = 45 kg/m2 (Body Mass Index) at Visit 1 (Screening)

          6. Signed and dated written informed consent by date of Visit 1 in accordance with Good
             Clinical Practice (GCP) and local legislation

        Exclusion criteria:

          1. Uncontrolled hyperglycaemia with a glucose level &gt; 240 mg/dl (&gt;13.3 mmol/L) after an
             overnight fast during placebo run-in and confirmed by a second measurement (not on the
             same day)

          2. Any other antidiabetic drug within 12 weeks prior to randomisation except those
             mentioned in inclusion criterion 2

          3. Myocardial infarction, stroke or transient ischemic attack (TIA) within 3 months prior
             to informed consent

          4. Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT),
             or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined during
             screening and/or run-in phase

          5. Impaired renal function, defined as eGFR&lt;30 ml/min (severe renal impairment) as
             determined during screening and/or run-in phase

          6. Bariatric surgery within the past two years and other gastrointestinal surgeries that
             induce chronic malabsorption

          7. Medical history of cancer (except for basal cell carcinoma) and/or treatment for
             cancer within the last 5 years

          8. Contraindications to metformin and/or sulfonylurea according to the local label for
             those patients that enter the study with the respective background therapy

          9. Blood dyscrasias or any disorders causing haemolysis or unstable Red Blood Cell (e.g.
             malaria, babesiosis, haemolytic anaemia)

         10. Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to
             informed consent or any other treatment at the time of screening (i.e. surgery,
             aggressive diet regimen, etc.) leading to unstable body weight

         11. Current treatment with systemic steroids at time of informed consent or change in
             dosage of thyroid hormones within 6 weeks prior to informed consent or any other
             uncontrolled endocrine disorder except Typ 2 Diabetes

         12. Pre-menopausal women (last menstruation ¿ 1 year prior to informed consent) who:

               -  are nursing or pregnant or

               -  are of child-bearing potential and are not practicing an acceptable method of
                  birth control, or do not plan to continue using this method throughout the study
                  and do not agree to submit to periodic pregnancy testing during participation in
                  the trial. Acceptable methods of birth control include tubal ligation,
                  transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable
                  or injectable contraceptives, sexual abstinence (if acceptable by local
                  authorities), double barrier method and vasectomised partner

         13. Alcohol or drug abuse within the 3 months prior to informed consent that would
             interfere with trial participation or any ongoing condition leading to a decreased
             compliance to study procedures or study drug intake

         14. Participation in another trial with an investigational drug within 30 days prior to
             informed consent

         15. Any other clinical condition that would jeopardize patients safety while participating
             in this clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.23.10145 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10095 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10074 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10149 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10127 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10133 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10080 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10159 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10117 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arkansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10157 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10148 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10123 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10120 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10158 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10156 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10153 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10143 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.10106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paradise</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Corunna</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.20038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ville Saint-Laurent</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haerbin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nan Ning</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nan Ning</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shantou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Xi'An</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.86051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zhenjiang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.33015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arras</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.33008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bersée</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.33020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bischheim</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.33002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bondy Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.33016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruay La Buissiere</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.33001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Corbeil Essonnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.33010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Croix</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.33009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hautmont</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.33003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Rochelle Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.33045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.33014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mundolsheim</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.33004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Narbonne Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.33012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schiltigheim</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.33013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.33019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.33007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vieux Condé</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.33018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wattrelos</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dormagen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Flörsheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hatten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Künzing</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuwied</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rednitzhembach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rehburg-Loccum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.49011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rehlingen-Siersburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saarbrücken</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Unterschneidheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.91101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.91104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Indore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.91103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.91102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.91105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.82012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.82011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.82009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.82007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.82008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.82010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.82014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.52003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.52004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.52001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.52002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.74005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.74002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lucenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.74006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.74014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nove Zamky</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.74001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Povazska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.74004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.74003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trebisov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Celje</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koper</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maribor</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.88010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.88011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.88012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.88013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.88009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.88014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.88006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.88007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.88021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.88008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taoyuan County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.90003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erzurum</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.90001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gaziantep</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.90002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.90006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.90007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.23.90004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2010</study_first_submitted>
  <study_first_submitted_qc>July 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2010</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>May 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2014</results_first_posted>
  <last_update_submitted>May 16, 2014</last_update_submitted>
  <last_update_submitted_qc>May 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Met: Placebo</title>
          <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks in patients with background medication of metformin only.</description>
        </group>
        <group group_id="P2">
          <title>Met: Empa 10mg</title>
          <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
        </group>
        <group group_id="P3">
          <title>Met: Empa 25mg</title>
          <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
        </group>
        <group group_id="P4">
          <title>Met: Empa 25mg Open Label</title>
          <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
        </group>
        <group group_id="P5">
          <title>Met+SU: Placebo</title>
          <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
        </group>
        <group group_id="P6">
          <title>Met+SU: Empa 10mg</title>
          <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
        </group>
        <group group_id="P7">
          <title>Met+SU: Empa 25mg</title>
          <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
        </group>
        <group group_id="P8">
          <title>Met+SU: Empa 25mg Open Label</title>
          <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
                <participants group_id="P2" count="217"/>
                <participants group_id="P3" count="214"/>
                <participants group_id="P4" count="69"/>
                <participants group_id="P5" count="225"/>
                <participants group_id="P6" count="226"/>
                <participants group_id="P7" count="218"/>
                <participants group_id="P8" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="186"/>
                <participants group_id="P2" count="209"/>
                <participants group_id="P3" count="196"/>
                <participants group_id="P4" count="58"/>
                <participants group_id="P5" count="201"/>
                <participants group_id="P6" count="208"/>
                <participants group_id="P7" count="199"/>
                <participants group_id="P8" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="24"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="19"/>
                <participants group_id="P8" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliant with protocol</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient refusal to continue,not due toAE</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS), which included all randomised patients treated with at least one dose of study drug with a baseline HbA1c value. Treatment assignment as randomised.
Open label set which included all patients entered in the empa 25mg open-label arm.</population>
      <group_list>
        <group group_id="B1">
          <title>Met: Placebo</title>
          <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks in patients with background medication of metformin only.</description>
        </group>
        <group group_id="B2">
          <title>Met: Empa 10mg</title>
          <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
        </group>
        <group group_id="B3">
          <title>Met: Empa 25mg</title>
          <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
        </group>
        <group group_id="B4">
          <title>Met: Empa 25mg Open Label</title>
          <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
        </group>
        <group group_id="B5">
          <title>Met+SU: Placebo</title>
          <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
        </group>
        <group group_id="B6">
          <title>Met+SU: Empa 10mg</title>
          <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
        </group>
        <group group_id="B7">
          <title>Met+SU: Empa 25mg</title>
          <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
        </group>
        <group group_id="B8">
          <title>Met+SU: Empa 25mg Open Label</title>
          <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="207"/>
            <count group_id="B2" value="217"/>
            <count group_id="B3" value="213"/>
            <count group_id="B4" value="69"/>
            <count group_id="B5" value="225"/>
            <count group_id="B6" value="225"/>
            <count group_id="B7" value="216"/>
            <count group_id="B8" value="101"/>
            <count group_id="B9" value="1473"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.0" spread="9.7"/>
                    <measurement group_id="B2" value="55.5" spread="9.9"/>
                    <measurement group_id="B3" value="55.6" spread="10.2"/>
                    <measurement group_id="B4" value="49.8" spread="11.5"/>
                    <measurement group_id="B5" value="56.9" spread="9.2"/>
                    <measurement group_id="B6" value="57.0" spread="9.2"/>
                    <measurement group_id="B7" value="57.4" spread="9.3"/>
                    <measurement group_id="B8" value="53.4" spread="10.5"/>
                    <measurement group_id="B9" value="55.9" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="113"/>
                    <measurement group_id="B6" value="112"/>
                    <measurement group_id="B7" value="102"/>
                    <measurement group_id="B8" value="47"/>
                    <measurement group_id="B9" value="678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="112"/>
                    <measurement group_id="B6" value="113"/>
                    <measurement group_id="B7" value="114"/>
                    <measurement group_id="B8" value="54"/>
                    <measurement group_id="B9" value="795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight Change From Baseline</title>
        <description>Body weight change from baseline after 24 weeks.
For open-label groups the descriptive mean is provided, for randomised groups adjusted means are provided. The means are adjusted separately for metformin alone and metformin plus sulphonylurea background medication.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Full analysis set. Treatment assignment as randomised.
Open-label analysis: Open-label set which included all patients entered in the empa 25mg open-label treatment arm.
Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Met: Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks in patients with background medication of metformin only.</description>
          </group>
          <group group_id="O2">
            <title>Met: Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
          </group>
          <group group_id="O3">
            <title>Met: Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
          </group>
          <group group_id="O4">
            <title>Met: Empa 25mg Open Label</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
          </group>
          <group group_id="O5">
            <title>Met+SU: Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
          </group>
          <group group_id="O6">
            <title>Met+SU: Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
          </group>
          <group group_id="O7">
            <title>Met+SU: Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
          </group>
          <group group_id="O8">
            <title>Met+SU: Empa 25mg Open Label</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight Change From Baseline</title>
          <description>Body weight change from baseline after 24 weeks.
For open-label groups the descriptive mean is provided, for randomised groups adjusted means are provided. The means are adjusted separately for metformin alone and metformin plus sulphonylurea background medication.</description>
          <population>Full analysis set. Treatment assignment as randomised.
Open-label analysis: Open-label set which included all patients entered in the empa 25mg open-label treatment arm.
Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="217"/>
                <count group_id="O3" value="213"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="225"/>
                <count group_id="O6" value="225"/>
                <count group_id="O7" value="216"/>
                <count group_id="O8" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.17"/>
                    <measurement group_id="O2" value="-2.08" spread="0.17"/>
                    <measurement group_id="O3" value="-2.46" spread="0.17"/>
                    <measurement group_id="O4" value="-1.33" spread="0.43"/>
                    <measurement group_id="O5" value="-0.39" spread="0.15"/>
                    <measurement group_id="O6" value="-2.16" spread="0.15"/>
                    <measurement group_id="O7" value="-2.39" spread="0.16"/>
                    <measurement group_id="O8" value="-1.29" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference in change from baseline to week 24 in body weight between Empagliflozin 10mg and placebo. A hierarchical testing approach was applied to each of the two dose comparisons (10mg vs placebo and 25mg vs placebo) within each background therapy group (metformin and metformin + SU). If for a specific dose the null hypothesis was rejected for the primary endpoint, the same dose was tested against placebo for the change from baseline in body weight.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Each of the hypotheses (10mg vs placebo and 25mg vs placebo) were tested (two-sided test) at the significance level of 0.025.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline HbA1c and baseline body weight as linear covariates and baseline eGFR, geographical region and treatment as fixed effects</method_desc>
            <param_type>Mean difference</param_type>
            <param_value>-1.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.17</ci_lower_limit>
            <ci_upper_limit>-1.08</ci_upper_limit>
            <estimate_desc>Difference calculated as Met: empa 10mg minus Met: placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference in change from baseline to week 24 in body weight between Empagliflozin 25mg and placebo. A hierarchical testing approach was applied to each of the two dose comparisons (10mg vs placebo and 25mg vs placebo) within each background therapy group (metformin and metformin + SU). If for a specific dose the null hypothesis was rejected for the primary endpoint, the same dose was tested against placebo for the change from baseline in body weight.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Each of the hypotheses (10mg vs placebo and 25mg vs placebo) were tested (two-sided test) at the significance level of 0.025.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline HbA1c and baseline body weight as linear covariates and baseline eGFR, geographical region and treatment as fixed effects</method_desc>
            <param_type>Mean difference</param_type>
            <param_value>-2.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.56</ci_lower_limit>
            <ci_upper_limit>-1.46</ci_upper_limit>
            <estimate_desc>Difference calculated as Met: empa 25mg minus Met: placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference in change from baseline to week 24 in body weight between Empagliflozin 10mg and placebo. A hierarchical testing approach was applied to each of the two dose comparisons (10mg vs placebo and 25mg vs placebo) within each background therapy group (metformin and metformin + SU). If for a specific dose the null hypothesis was rejected for the primary endpoint, the same dose was tested against placebo for the change from baseline in body weight.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Each of the hypotheses (10mg vs placebo and 25mg vs placebo) were tested (two-sided test) at the significance level of 0.025.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline HbA1c and baseline body weight as linear covariates and baseline eGFR, geographical region and treatment as fixed effects</method_desc>
            <param_type>Mean difference</param_type>
            <param_value>-1.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.25</ci_lower_limit>
            <ci_upper_limit>-1.28</ci_upper_limit>
            <estimate_desc>Difference calculated as Met+SU: empa 10mg minus Met+SU: placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference in change from baseline to week 24 in body weight between Empagliflozin 25mg and placebo. A hierarchical testing approach was applied to each of the two dose comparisons (10mg vs placebo and 25mg vs placebo) within each background therapy group (metformin and metformin + SU). If for a specific dose the null hypothesis was rejected for the primary endpoint, the same dose was tested against placebo for the change from baseline in body weight.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Each of the hypotheses (10mg vs placebo and 25mg vs placebo) were tested (two-sided test) at the significance level of 0.025.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline HbA1c and baseline body weight as linear covariates and baseline eGFR, geographical region and treatment as fixed effects</method_desc>
            <param_type>Mean difference</param_type>
            <param_value>-1.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.48</ci_lower_limit>
            <ci_upper_limit>-1.50</ci_upper_limit>
            <estimate_desc>Difference calculated as Met+SU: empa 25mg minus Met+SU: placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Daily Plasma Glucose (MDG) Change From Baseline</title>
        <description>Change from baseline in mean daily glucose (MDG) using the 8-point blood glucose profile, after 24 weeks of treatment.
For open-label groups the descriptive mean is provided, for randomised groups adjusted means are provided. The means are adjusted separately for metformin alone and metformin plus sulphonylurea background medication.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Full analysis set. Treatment assignment as randomised.
Open-label analysis: Open-label set which included all patients entered in the empa 25mg open-label treatment arm.
Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Met: Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks in patients with background medication of metformin only.</description>
          </group>
          <group group_id="O2">
            <title>Met: Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
          </group>
          <group group_id="O3">
            <title>Met: Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
          </group>
          <group group_id="O4">
            <title>Met: Empa 25mg Open Label</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
          </group>
          <group group_id="O5">
            <title>Met+SU: Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
          </group>
          <group group_id="O6">
            <title>Met+SU: Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
          </group>
          <group group_id="O7">
            <title>Met+SU: Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
          </group>
          <group group_id="O8">
            <title>Met+SU: Empa 25mg Open Label</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Daily Plasma Glucose (MDG) Change From Baseline</title>
          <description>Change from baseline in mean daily glucose (MDG) using the 8-point blood glucose profile, after 24 weeks of treatment.
For open-label groups the descriptive mean is provided, for randomised groups adjusted means are provided. The means are adjusted separately for metformin alone and metformin plus sulphonylurea background medication.</description>
          <population>Full analysis set. Treatment assignment as randomised.
Open-label analysis: Open-label set which included all patients entered in the empa 25mg open-label treatment arm.
Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="151"/>
                <count group_id="O6" value="148"/>
                <count group_id="O7" value="117"/>
                <count group_id="O8" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.99" spread="1.99"/>
                    <measurement group_id="O2" value="-9.64" spread="1.89"/>
                    <measurement group_id="O3" value="-14.36" spread="1.89"/>
                    <measurement group_id="O4" value="-35.47" spread="7.34"/>
                    <measurement group_id="O5" value="0.00" spread="1.78"/>
                    <measurement group_id="O6" value="-10.01" spread="1.80"/>
                    <measurement group_id="O7" value="-13.06" spread="2.03"/>
                    <measurement group_id="O8" value="-29.34" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis (H0): No difference in change from baseline to week 24 in MDG between Empa 10mg and placebo. A hierarchical testing approach was applied to each of the two dose comparisons within each background therapy group. If for a specific dose H0 was rejected for the primary endpoint, the same dose was tested against placebo for change from baseline in body weight. If superiority over placebo was shown at this gate level, then testing proceeded to change from baseline in MDG with that dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0055</p_value>
            <p_value_desc>Each of the hypotheses (10mg vs placebo and 25mg vs placebo) were tested (two-sided test) at the significance level of 0.025.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with baseline HbA1c and baseline MDG as linear covariates and baseline eGFR, geographical region and treatment as fixed effects.</method_desc>
            <param_type>Mean difference</param_type>
            <param_value>-7.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.74</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.81</ci_lower_limit>
            <ci_upper_limit>-1.48</ci_upper_limit>
            <estimate_desc>Difference calculated as Met: empa 10mg minus Met: placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis (H0): No difference in change from baseline to week 24 in MDG between Empa 25mg and placebo. A hierarchical testing approach was applied to each of the two dose comparisons within each background therapy group. If for a specific dose H0 was rejected for the primary endpoint, the same dose was tested against placebo for change from baseline in body weight. If superiority over placebo was shown at this gate level, then testing proceeded to change from baseline in MDG with that dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Each of the hypotheses (10mg vs placebo and 25mg vs placebo) were tested (two-sided test) at the significance level of 0.025.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with baseline HbA1c and baseline MDG as linear covariates and baseline eGFR, geographical region and treatment as fixed effects.</method_desc>
            <param_type>Mean difference</param_type>
            <param_value>-12.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.75</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.55</ci_lower_limit>
            <ci_upper_limit>-6.19</ci_upper_limit>
            <estimate_desc>Difference calculated as Met: empa 25mg minus Met: placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis (H0): No difference in change from baseline to week 24 in MDG between Empa 10mg and placebo. A hierarchical testing approach was applied to each of the two dose comparisons within each background therapy group. If for a specific dose H0 was rejected for the primary endpoint, the same dose was tested against placebo for change from baseline in body weight. If superiority over placebo was shown at this gate level, then testing proceeded to change from baseline in MDG with that dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Each of the hypotheses (10mg vs placebo and 25mg vs placebo) were tested (two-sided test) at the significance level of 0.025.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with baseline HbA1c and baseline MDG as linear covariates and baseline eGFR, geographical region and treatment as fixed effects.</method_desc>
            <param_type>Mean difference</param_type>
            <param_value>-10.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.53</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.72</ci_lower_limit>
            <ci_upper_limit>-4.32</ci_upper_limit>
            <estimate_desc>Difference calculated as Met+SU: empa 10mg minus Met+SU: placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis (H0): No difference in change from baseline to week 24 in MDG between Empa 25mg and placebo. A hierarchical testing approach was applied to each of the two dose comparisons within each background therapy group. If for a specific dose H0 was rejected for the primary endpoint, the same dose was tested against placebo for change from baseline in body weight. If superiority over placebo was shown at this gate level, then testing proceeded to change from baseline in MDG with that dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Each of the hypotheses (10mg vs placebo and 25mg vs placebo) were tested (two-sided test) at the significance level of 0.025.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with baseline HbA1c and baseline MDG as linear covariates and baseline eGFR, geographical region and treatment as fixed effects.</method_desc>
            <param_type>Mean difference</param_type>
            <param_value>-13.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.70</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.15</ci_lower_limit>
            <ci_upper_limit>-6.98</ci_upper_limit>
            <estimate_desc>Difference calculated as Met+SU: empa 25mg minus Met+SU: placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HbA1c Change From Baseline</title>
        <description>Change from baseline in HbA1c after 24 weeks.
For open-label groups the descriptive mean is provided, for randomised groups adjusted means are provided. The means are adjusted separately for metformin alone and metformin plus sulphonylurea background medication.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Full analysis set. Treatment assignment as randomised.
Open-label analysis: Open-label set which included all patients entered in the empa 25mg open-label treatment arm.
Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Met: Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks, in patients with background medication of metformin only.</description>
          </group>
          <group group_id="O2">
            <title>Met: Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
          </group>
          <group group_id="O3">
            <title>Met: Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
          </group>
          <group group_id="O4">
            <title>Met: Empa 25mg Open Label</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
          </group>
          <group group_id="O5">
            <title>Met+SU: Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
          </group>
          <group group_id="O6">
            <title>Met+SU: Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
          </group>
          <group group_id="O7">
            <title>Met+SU: Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
          </group>
          <group group_id="O8">
            <title>Met+SU: Empa 25mg Open Label</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change From Baseline</title>
          <description>Change from baseline in HbA1c after 24 weeks.
For open-label groups the descriptive mean is provided, for randomised groups adjusted means are provided. The means are adjusted separately for metformin alone and metformin plus sulphonylurea background medication.</description>
          <population>Full analysis set. Treatment assignment as randomised.
Open-label analysis: Open-label set which included all patients entered in the empa 25mg open-label treatment arm.
Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="217"/>
                <count group_id="O3" value="213"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="225"/>
                <count group_id="O6" value="225"/>
                <count group_id="O7" value="216"/>
                <count group_id="O8" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.05"/>
                    <measurement group_id="O2" value="-0.70" spread="0.05"/>
                    <measurement group_id="O3" value="-0.77" spread="0.05"/>
                    <measurement group_id="O4" value="-2.78" spread="0.21"/>
                    <measurement group_id="O5" value="-0.17" spread="0.05"/>
                    <measurement group_id="O6" value="-0.82" spread="0.05"/>
                    <measurement group_id="O7" value="-0.77" spread="0.05"/>
                    <measurement group_id="O8" value="-2.53" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference in change from baseline to week 24 in HbA1c between Empagliflozin 10mg and placebo. The study consisted of two substudies as defined by the two background medications 'metformin' and 'metformin + SU'. Within each group of background medication, each of the two hypotheses (10mg vs placebo and 25mg vs. placebo) was tested in a two-sided test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Each of the hypotheses (10mg vs placebo and 25mg vs. placebo) were tested (two-sided test) at the significance level of 0.025.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with baseline HbA1c as a linear covariate and baseline eGFR (renal function), geographical region and treatment as fixed effects.</method_desc>
            <param_type>Mean difference</param_type>
            <param_value>-0.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>-0.42</ci_upper_limit>
            <estimate_desc>Difference calculated as Met: empa 10mg minus Met: placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference in change from baseline to week 24 in HbA1c between Empagliflozin 25mg and placebo. The study consisted of two substudies as defined by the two background medications 'metformin' and 'metformin + SU'. Within each group of background medication, each of the two hypotheses (10mg vs placebo and 25mg vs. placebo) was tested in a two-sided test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Each of the hypotheses (10mg vs placebo and 25mg vs. placebo) were tested (two-sided test) at the significance level of 0.025.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with baseline HbA1c as a linear covariate and baseline eGFR, geographical region and treatment as fixed effects.</method_desc>
            <param_type>Mean difference</param_type>
            <param_value>-0.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.79</ci_lower_limit>
            <ci_upper_limit>-0.48</ci_upper_limit>
            <estimate_desc>Difference calculated as Met: empa 25mg minus Met: placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference in change from baseline to week 24 in HbA1c between Empagliflozin 10mg and placebo. The study consisted of two substudies as defined by the two background medications 'metformin' and 'metformin + SU'. Within each group of background medication, each of the two hypotheses (10mg vs placebo and 25mg vs. placebo) was tested in a two-sided test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Each of the hypotheses (10mg vs placebo and 25mg vs. placebo) were tested (two-sided test) at the significance level of 0.025.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with baseline HbA1c as a linear covariate and baseline eGFR, geographical region and treatment as fixed effects.</method_desc>
            <param_type>Mean difference</param_type>
            <param_value>-0.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.79</ci_lower_limit>
            <ci_upper_limit>-0.49</ci_upper_limit>
            <estimate_desc>Difference calculated as Met+SU: empa 10mg minus Met+SU: placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference in change from baseline to week 24 in HbA1c between Empagliflozin 25mg and placebo. The study consisted of two substudies as defined by the two background medications 'metformin' and 'metformin + SU'. Within each group of background medication, each of the two hypotheses (10mg vs placebo and 25mg vs. placebo) was tested in a two-sided test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Each of the hypotheses (10mg vs placebo and 25mg vs. placebo) were tested (two-sided test) at the significance level of 0.025.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with baseline HbA1c as a linear covariate and baseline eGFR, geographical region and treatment as fixed effects.</method_desc>
            <param_type>Mean difference</param_type>
            <param_value>-0.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.74</ci_lower_limit>
            <ci_upper_limit>-0.44</ci_upper_limit>
            <estimate_desc>Difference calculated as Met+SU: empa 25mg minus Met+SU: placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Confirmed Hypoglycaemic Adverse Events</title>
        <description>Number of patients with confirmed hypoglycaemic events, as reported as adverse events.</description>
        <time_frame>From first intake of randomised trial medication until 7 days after last trial medication intake, up to 231 days</time_frame>
        <population>Treated set, which included all patients treated with at least one dose of randomised trial medication. Treatment assignment as first medication taken.
Open label set which included all patients entered into the open-label arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Met: Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks in patients with background medication of metformin only.</description>
          </group>
          <group group_id="O2">
            <title>Met: Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
          </group>
          <group group_id="O3">
            <title>Met: Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
          </group>
          <group group_id="O4">
            <title>Met: Empa 25mg Open Label</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
          </group>
          <group group_id="O5">
            <title>Met+SU: Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
          </group>
          <group group_id="O6">
            <title>Met+SU: Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
          </group>
          <group group_id="O7">
            <title>Met+SU: Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
          </group>
          <group group_id="O8">
            <title>Met+SU: Empa 25mg Open Label</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Hypoglycaemic Adverse Events</title>
          <description>Number of patients with confirmed hypoglycaemic events, as reported as adverse events.</description>
          <population>Treated set, which included all patients treated with at least one dose of randomised trial medication. Treatment assignment as first medication taken.
Open label set which included all patients entered into the open-label arm.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="217"/>
                <count group_id="O3" value="214"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="225"/>
                <count group_id="O6" value="224"/>
                <count group_id="O7" value="217"/>
                <count group_id="O8" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.01"/>
                    <measurement group_id="O2" value="1.8" spread="0.01"/>
                    <measurement group_id="O3" value="1.4" spread="0.03"/>
                    <measurement group_id="O4" value="2.9" spread="0.02"/>
                    <measurement group_id="O5" value="8.4" spread="0.01"/>
                    <measurement group_id="O6" value="16.1" spread="0.01"/>
                    <measurement group_id="O7" value="11.5" spread="0.03"/>
                    <measurement group_id="O8" value="6.9" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first intake of randomised trial medication until 7 days after last trial medication intake, up to 231 days</time_frame>
      <desc>Treated set which included all patients treated with at least one dose of randomised trial medication. Treatment assignment as first medication taken.
Open label set which included all patients entered into the open-label arm</desc>
      <group_list>
        <group group_id="E1">
          <title>Met: Placebo</title>
          <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks in patients with background medication of metformin only.</description>
        </group>
        <group group_id="E2">
          <title>Met: Empa 10mg</title>
          <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
        </group>
        <group group_id="E3">
          <title>Met: Empa 25mg</title>
          <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
        </group>
        <group group_id="E4">
          <title>Met: Empa 25mg Open Label</title>
          <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin only.</description>
        </group>
        <group group_id="E5">
          <title>Met+SU: Placebo</title>
          <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
        </group>
        <group group_id="E6">
          <title>Met+SU: Empa 10mg</title>
          <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
        </group>
        <group group_id="E7">
          <title>Met+SU: Empa 25mg</title>
          <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
        </group>
        <group group_id="E8">
          <title>Met+SU: Empa 25mg Open Label</title>
          <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Listeria sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Post-traumatic neck syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Syringomyelia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="76" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="77" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="67" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="28" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infections</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="28" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="225"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="224"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="217"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

